Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic
tissues.
Authors
Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, Galiano RD, Du XL,
Grogan R, Galvez MG, Januszyk M, Brownlee M, Gurtner GC
Submitted By
Geoffrey Gurtner on 3/31/2010
Status
Published
Journal
Proceedings of the National Academy of Sciences of the United States of America
Year
2009
Date Published
8/11/2009
Volume : Pages
106 : 13505 - 13510
PubMed Reference
19666581
Abstract
Diabetes is associated with poor outcomes following acute vascular occlusive
events. This results in part from a failure to form adequate compensatory
microvasculature in response to ischemia. Since vascular endothelial growth
factor (VEGF) is an essential mediator of neovascularization, we examined
whether hypoxic up-regulation of VEGF was impaired in diabetes. Both fibroblasts
isolated from type 2 diabetic patients, and normal fibroblasts exposed
chronically to high glucose, were defective in their capacity to up-regulate
VEGF in response to hypoxia. In vivo, diabetic animals demonstrated an impaired
ability to increase VEGF production in response to soft tissue ischemia. This
resulted from a high glucose-induced decrease in transactivation by the
transcription factor hypoxia-inducible factor-1alpha (HIF-1alpha), which
mediates hypoxia-stimulated VEGF expression. Decreased HIF-1alpha functional
activity was specifically caused by impaired HIF-1alpha binding to the
coactivator p300. We identify covalent modification of p300 by the dicarbonyl
metabolite methylglyoxal as being responsible for this decreased association.
Administration of deferoxamine abrogated methylglyoxal conjugation, normalizing
both HIF-1alpha/p300 interaction and transactivation by HIF-1alpha. In diabetic
mice, deferoxamine promoted neovascularization and enhanced wound healing. These
findings define molecular defects that underlie impaired VEGF production in
diabetic tissues and offer a promising direction for therapeutic intervention.
Investigators with authorship
Name
Institution
Geoffrey Gurtner
Stanford University
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Genes
Symbol
Description
Ep300
E1A binding protein p300
Hif1a
hypoxia inducible factor 1, alpha subunit
Notch1
Notch gene homolog 1, (Drosophila)
Vegfa
vascular endothelial growth factor A
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!